MEDIPURE ANNOUNCES KEY ADDITION TO TAKE COMPANY TO NEXT STAGE OF DEVELOPMENT

Vancouver, BC – February, 2019 - Medipure Holdings Inc., a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms, today announced the appointment of Alan C. Mendelson as Corporate Secretary and Advisor to the Board of Directors.

Alan C. Mendelson, a senior partner of the global law firm Latham & Watkins LLP, represents emerging and public growth companies primarily in the life-sciences industry. He has managed and supervised a variety of major business transactions including public offerings.

“The development of our company very much relies on the talent we assemble with respect to research and innovation," said Boris Weiss, CEO of Medipure; "however, an emerging company in this field also requires the experience that Mr. Mendelson will bring to the table - and we believe he will be invaluable in moving Medipure to its next stage of development.“

Mr. Mendelson served as the Co-Chair of Latham & Watkins Emerging Companies Practice from 2001 to 2013 and is currently Co-Chair of the Life Sciences Industry Group.

For more information, please visit: http://medipurepharmaceuticals.com

 

ABOUT MEDIPURE
Medipure is a biopharmaceutical incubator committed to discovering and developing proprietary endocannabinoid system-based prescription drugs for targeted diseases by regulating specific molecular mechanisms. Our core products target specific disease areas including pain management, mood disorders/anxiety, nausea, appetite, oncology, arthritis, dermatology and fatty liver disease (NASH). Medipure Pharmaceuticals’ research and development is focused on having the greatest impact and benefit for patients worldwide. At the same time, we aim to make sure that our products are approved by regulators and well understood by physicians, healthcare providers and prospective patients.